Below are the details for the FACT-EGFRI-18 measure:
Functional Assessment of Cancer Therapy - Epidermal Growth Factor Inhibitors 18 Item Version (FACT-EGFRI-18)
NUMBER OF ITEMS:
Cancer patients 18 years and older undergoing EGFR treatment
Past 7 days
5 point Likert-type scale
Paper and electronic
Self-administration and interview when applicable
TIME FOR COMPLETION:
Manual scoring template, some items are reverse scored. Total scores possible.
Available translations of the FACT-EGFRI-18 can be obtained by registering for permission. Users are not permitted to translate the FACT-EGFRI-18 without permission from FACIT.org. Permission from FACIT.org to translate the FACT-EGFRI-18 may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system.
Please contact us for more information.
Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained.
Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use.
To license an available version of this measure for commercial or non-commercial use, please complete our registration form. All of the information provided in the form will be kept strictly confidential. For questions, please contact us.
Boers-Doets, C., Gelderblom, H., Lacouture, M. Bredle, J., Epstein, J., Schrama, N., Gall, H., Ouwerkerk, J., Brakenhoff, J., Nortier, J.,& Kaptein, A. Translation and linguistic validation of the FACT-EGFRI-18 quality of life instrument from English into Dutch. European Journal of Oncology Nursing 2013; 17(6): 802-807. doi: 10.1016/j.ejon.2013.03.004.
Wagner, L., Berg, S., Gandhi, M., Hlubocky, F., Webster, K., Aneja, M., Cella, D., & Lacouture, M. The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18). Journal of Supportive Care in Cancer 2014; 21(4): 1033-1041. Doi: 10.1007/s00520-012-1623-4.
Wong SF, Unger JM, Wade JL 3rd, Wagner LI, Lacouture ME, Humphries KC, Moseley A, Arnold K, Velasco MR Jr, Floyd JD, Esparaz BT, Barzi A, Lenz HJ, Koczywas M, Dakhil S, Burton GV, Fisch MJ, Henry NL, Hershman DL, Moinpour CM. A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013. J Patient Rep Outcomes. 2020 Jul 8;4(1):54. doi: 10.1186/s41687-020-00220-x. PMID: 32642992; PMCID: PMC7343679.
Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320.
Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232.
Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85.
Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191.